- Home
- GNSS vs ATOS Comparison
GNSS vs ATOS Comparison
Compare GNSS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- ATOS
- Stock Information
- Founded
- GNSS 1992
- ATOS 2009
- Country
- GNSS United States
- ATOS United States
- Employees
- GNSS N/A
- ATOS N/A
- Industry
- GNSS Consumer Electronics/Appliances
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- ATOS Health Care
- Exchange
- GNSS Nasdaq
- ATOS Nasdaq
- Market Cap
- GNSS N/A
- ATOS 96.8M
- IPO Year
- GNSS N/A
- ATOS 2012
- Fundamental
- Price
- GNSS $2.19
- ATOS $0.69
- Analyst Decision
- GNSS Strong Buy
- ATOS Strong Buy
- Analyst Count
- GNSS 3
- ATOS 3
- Target Price
- GNSS $5.33
- ATOS $7.00
- AVG Volume (30 Days)
- GNSS 131.2K
- ATOS 527.1K
- Earning Date
- GNSS 05-13-2025
- ATOS 05-12-2025
- Dividend Yield
- GNSS N/A
- ATOS N/A
- EPS Growth
- GNSS N/A
- ATOS N/A
- EPS
- GNSS N/A
- ATOS N/A
- Revenue
- GNSS $26,587,000.00
- ATOS N/A
- Revenue This Year
- GNSS $121.93
- ATOS N/A
- Revenue Next Year
- GNSS $68.26
- ATOS N/A
- P/E Ratio
- GNSS N/A
- ATOS N/A
- Revenue Growth
- GNSS N/A
- ATOS N/A
- 52 Week Low
- GNSS $1.65
- ATOS $0.65
- 52 Week High
- GNSS $4.04
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- GNSS 35.71
- ATOS 41.11
- Support Level
- GNSS $2.30
- ATOS $0.65
- Resistance Level
- GNSS $2.45
- ATOS $0.71
- Average True Range (ATR)
- GNSS 0.12
- ATOS 0.04
- MACD
- GNSS 0.01
- ATOS -0.00
- Stochastic Oscillator
- GNSS 5.88
- ATOS 31.33
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.